Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

Table 5 Change in total discounted lifetime costs (2010 US$) and quality adjusted life years of boceprevir-based regimens compared with PR48 in multi-way sensitivity and subset analyses

	BOC/RGT vs. PR48			BOC/PR48 vs. PR48
	Discounted costs	Discounted QALYs	ICER	Discounted costs	Discounted QALYs	ICER
Base	10,348	0.62	16,792	35,727	0.65	55,162
Sensitivity Analyses
Discount rate for costs = 0%, discount rate for utilities = 0%	2,868	1.23	2,338	27,870	1.33	21,016
Discount rate for costs = 5%, discount rate for utilities = 5%	12,894	0.42	30,630	38,256	0.43	88,789
Lower Bound of Transition Rates	12,126	0.43	28,314	37,703	0.44	85,867
Upper Bound of Transition Rates	11,032	0.83	13,340	36,485	0.88	41,393
Lower Bound for Health State Costs	12,538	0.62	20,346	38,165	0.65	58,927
Upper Bound for Health State Costs	8,158	0.62	13,239	33,288	0.65	51,397
Lower Bound for Population Average Utilities	10,348	0.61	17,097	35,727	0.64	56,228
Upper Bound for Population Average Utilities	10,348	0.63	16,508	35,727	0.66	54,133
Lower Bound for On Treatment Utilities	10,348	0.62	16,724	35,727	0.64	56,120
Upper Bound for On Treatment Utilities	10,348	0.62	16,819	35,727	0.66	53,800
Lower Bound for Utilities of SVR states	10,348	0.31	33,511	35,727	0.30	117,395
Upper Bound for Utilities of SVR states	10,348	0.62	16,792	35,727	0.65	55,162
Lower Bound for Health State Utilities	10,348	0.95	10,906	35,727	1.02	34,927
Upper Bound for Health State Utilities	10,348	0.33	31,124	35,727	0.33	108,965
Subset Analyses
Non-Black Cohort	9,655	0.64	15,067	35,968	0.64	56,013
Black Cohort	14,437	0.47	30,627	34,305	0.68	50,423
	BOC regimen vs. PR48
	Discounted Costs	Discounted Utilities	ICER
Label-Based Analyses	18,046	0.66	27,265

PR48 – peginterferon-ribavirin regimen for 48 weeks; BOC/RGT – peginterferon–ribavirin for 4 weeks followed by peginterferon-ribavirin and boceprevir for 24 weeks, and those with a detectable hepatitis C virus (HCV) RNA level between weeks 8 and 24 received peginterferon–ribavirin from week 28 to week 48; BOC/PR48 –peginterferon–ribavirin for 48 weeks and boceprevir for 44 weeks.